Bogusłąw O.
- Country
- Poland
- Department
- n/a
Research Overview
- A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Plozasiran in Adults with Severe Hypertriglyceridemia
- A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active-Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation
- Phase 3 Open-Label Extension Study on Long-Term Safety and Efficacy of Plozasiran in Adults with Hypertriglyceridemia Using Synthetic siRNA Oligonucleotide
Data & Insights
Has run more than one trial at 141 of 571 partner sites.
Specializations
Cardiovascular Medicine
This investigator specializes in the treatment and management of atrial fibrillation, with particular focus on preventing cardioembolic events and exploring innovative anticoagulation therapies.
- Stroke Prevention
- Systemic Embolism Management
- Novel Anticoagulation Approaches
The research involves evaluating new therapeutic agents for patients with cardiac conditions requiring anticoagulation treatment.
Metabolic Disorders
The investigator conducts research in metabolic conditions, particularly focusing on severe hypertriglyceridemia and lipid disorders.
- Triglyceride Level Management
- Lipid Metabolism
- Metabolic Disease Treatment
Their work encompasses innovative therapeutic approaches for managing severe metabolic conditions affecting lipid processing.
Rare Diseases
The investigator studies rare metabolic conditions, with specific expertise in partial lipodystrophy and its associated complications.
- Familial Partial Lipodystrophy
- Metabolic Complications
- Hormone Replacement Therapy
The research focuses on developing treatments for rare metabolic disorders affecting fat tissue distribution and metabolism.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.